<DOC>
	<DOCNO>NCT02475265</DOCNO>
	<brief_summary>Decreased bone strength common serious medical problem present many woman anorexia nervosa . Women decrease bone strength likely suffer break bone woman normal bone strength . This study investigate whether use transdermal estrogen improve bone mineral density ( BMD ) bone microarchitecture woman anorexia nervosa anorexia nervosa use 6 month .</brief_summary>
	<brief_title>Transdermal Estrogen Older Premenopausal Women With Anorexia Nervosa</brief_title>
	<detailed_description>Anorexia nervosa ( AN ) prevalent psychiatric disorder affect 1 % college-aged woman US increase number woman 30 year age . Among many medical co-morbidities associate AN , common significant bone loss , persist despite weight recovery . Nearly 50 % woman AN osteopenia additional 30 % meeting WHO criteria osteoporosis . Importantly , severe bone loss associate increased fracture risk . Nearly 30 % woman AN report history fracture prospective study demonstrate 7-fold increased risk fracture woman AN compare age-matched control . Because AN chronic disease persist despite psychiatric nutritional counseling , bone loss increase fracture risk persist lead lifelong morbidity . Therefore , find treatment bone loss associate AN critical importance . This 6 month open-label study investigate woman ( age 30 50 year old ) AN whether treatment transdermal estrogen replacement increase bone mineral density ( BMD ) , improve parameter bone microarchitecture assess high-resolution peripheral quantitative compute tomography ( HR-pQCT ) , improve bone strength estimate microfinite element analysis .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Female ; age 3050 year Diagnostic Statistical Manual Mental Disorders , 5th Edition ( DSMV ) psychiatric criterion AN , include &lt; 85 % ideal body weight defined 1983 Metropolitan Life Insurance Height Weight Tables , amenorrhea Tscore &lt; 1.5 spine hip Treatment team treatment professional place clinical treatment/monitoring study Diseases know affect bone metabolism , include untreated thyroid dysfunction , vitamin D deficiency , Cushing 's syndrome , diabetes mellitus renal insufficiency Personal history venous arterial clot History stroke myocardial infarction History migraine headache History hypercoagulable disorder Personal history history firstdegree relative breast cancer History hereditary angioedema Any medication know affect bone metabolism , include systemic glucocorticoid within three month baseline visit , depot medroxyprogesterone within 6 month baseline visit , oral bisphosphonates within one year baseline visit intravenous ( IV ) bisphosphonates within three year baseline visit Bone fracture within prior 12 month Serum potassium &lt; 3.0 meq/L serum alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal Fasting serum triglyceride level &gt; 150 mg/dL Pregnant breastfeed Active substance abuse</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Anorexia Nervosa</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Eating Disorder</keyword>
	<keyword>Disordered Eating</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Bone</keyword>
</DOC>